Neuroimaging Biomarkers of mTOR Inhibition on Vascular and Metabolic Functions in Aging Brain and Alzheimer’s Disease

Jennifer Lee, Lucille M. Yanckello, David Ma, Jared D. Hoffman, Ishita Parikh, Scott Thalman, Bjoern Bauer, Anika M.S. Hartz, Fahmeed Hyder, Ai Ling Lin

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The mechanistic target of rapamycin (mTOR) is a nutrient sensor of eukaryotic cells. Inhibition of mechanistic mTOR signaling can increase life and health span in various species via interventions that include rapamycin and caloric restriction (CR). In the central nervous system, mTOR inhibition demonstrates neuroprotective patterns in aging and Alzheimer’s disease (AD) by preserving mitochondrial function and reducing amyloid beta retention. However, the effects of mTOR inhibition for in vivo brain physiology remain largely unknown. Here, we review recent findings of in vivo metabolic and vascular measures using non-invasive, multimodal neuroimaging methods in rodent models for brain aging and AD. Specifically, we focus on pharmacological treatment (e.g., rapamycin) for restoring brain functions in animals modeling human AD; nutritional interventions (e.g., CR and ketogenic diet) for enhancing brain vascular and metabolic functions in rodents at young age (5–6 months of age) and preserving those functions in aging (18–20 months of age). Various magnetic resonance (MR) methods [i.e., imaging (MRI), angiography (MRA), and spectroscopy (MRS)], confocal microscopic imaging, and positron emission tomography (PET) provided in vivo metabolic and vascular measures. We also discuss the translational potential of mTOR interventions. Since PET and various MR neuroimaging methods, as well as the different interventions (e.g., rapamycin, CR, and ketogenic diet) are also available for humans, these findings may have tremendous implications in future clinical trials of neurological disorders in aging populations.

Original languageEnglish
Article number225
JournalFrontiers in Aging Neuroscience
StatePublished - Jul 26 2018

Bibliographical note

Funding Information:
Funding. The studies were supported by National Institutes of Health (NIH)/National Institute on Aging (NIA) Grant K01AG040164, NIH/NIA Grant R01AG054459, NIH/CTSA Grant UL1TR000117, and American Federation for Aging Research Grant #A12474 to A-LL, NIH/NIA Grant R01AG039621 to AH, NIH/NINDS Grant R01NS079507 to BB, NIH/NIMH Grant R01MH067528 to FH, and NIH Training Grant T32DK007778 to JH, and T32AG057461 to ST.

Publisher Copyright:
© Copyright © 2018 Lee, Yanckello, Ma, Hoffman, Parikh, Thalman, Bauer, Hartz, Hyder and Lin.


  • Aging
  • Alzheimer’s disease
  • MRI
  • PET
  • caloric restriction
  • ketogentic diet
  • mechanistic target of rapamycin (mTOR)
  • rapamycin

ASJC Scopus subject areas

  • Aging
  • Cognitive Neuroscience


Dive into the research topics of 'Neuroimaging Biomarkers of mTOR Inhibition on Vascular and Metabolic Functions in Aging Brain and Alzheimer’s Disease'. Together they form a unique fingerprint.

Cite this